[go: up one dir, main page]

WO2001077294A3 - Hpv-specific short-mers - Google Patents

Hpv-specific short-mers Download PDF

Info

Publication number
WO2001077294A3
WO2001077294A3 PCT/US2001/040501 US0140501W WO0177294A3 WO 2001077294 A3 WO2001077294 A3 WO 2001077294A3 US 0140501 W US0140501 W US 0140501W WO 0177294 A3 WO0177294 A3 WO 0177294A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
replication
mers
provides
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/040501
Other languages
French (fr)
Other versions
WO2001077294A2 (en
Inventor
Radhakrishnan Iyer
Yi Jin
Wenqiang Zhou
Arlene Roland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origenix Technologies Inc
Original Assignee
Origenix Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenix Technologies Inc filed Critical Origenix Technologies Inc
Priority to CA002406485A priority Critical patent/CA2406485A1/en
Priority to AU2001257604A priority patent/AU2001257604A1/en
Priority to EP01931140A priority patent/EP1315507A4/en
Priority to JP2001575148A priority patent/JP2004501614A/en
Publication of WO2001077294A2 publication Critical patent/WO2001077294A2/en
Publication of WO2001077294A3 publication Critical patent/WO2001077294A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides oligonucleotides capable of inhibiting human papillomavirus (HPV) replication. More specifically, the invention provides oligonucleotides complementary to the translational start site of the HPV E1 open reading frame which inhibit HPV replication through interaction with a nucleic acid or a protein target. Oligonucleotides of the invention contain at least 4 deoxyribonucleotides and/or ribonucleotides and may include a variety of modifications to the internucleotide linkages or the mononucleotides. Furthermore, the invention provides pharmaceutical compositions and methods for treating disorders or diseases associated with HPV infection.
PCT/US2001/040501 2000-04-11 2001-04-11 Hpv-specific short-mers Ceased WO2001077294A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002406485A CA2406485A1 (en) 2000-04-11 2001-04-11 Hpv-specific short-mers
AU2001257604A AU2001257604A1 (en) 2000-04-11 2001-04-11 HPV-specific short-mers
EP01931140A EP1315507A4 (en) 2000-04-11 2001-04-11 Hpv-specific short-mers
JP2001575148A JP2004501614A (en) 2000-04-11 2001-04-11 HPV-specific shortmers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19599600P 2000-04-11 2000-04-11
US60/195,996 2000-04-11

Publications (2)

Publication Number Publication Date
WO2001077294A2 WO2001077294A2 (en) 2001-10-18
WO2001077294A3 true WO2001077294A3 (en) 2002-04-04

Family

ID=22723690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040501 Ceased WO2001077294A2 (en) 2000-04-11 2001-04-11 Hpv-specific short-mers

Country Status (5)

Country Link
EP (1) EP1315507A4 (en)
JP (1) JP2004501614A (en)
AU (1) AU2001257604A1 (en)
CA (1) CA2406485A1 (en)
WO (1) WO2001077294A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632938B2 (en) * 2001-06-07 2003-10-14 Isis Pharmaceuticals, Inc. Processes of purifying oligonucleotides
WO2011144216A1 (en) * 2010-05-19 2011-11-24 Tartu Ulikool (University Of Tartu) Method and kit for identifying compounds capable of inhibiting human papilloma virus replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425995A2 (en) * 1989-11-03 1991-05-08 Abbott Laboratories Use of conserved oligonucleotide primers to amplify human papillomavirus DNA sequences
WO1995004748A1 (en) * 1993-08-09 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating viral processes
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425995A2 (en) * 1989-11-03 1991-05-08 Abbott Laboratories Use of conserved oligonucleotide primers to amplify human papillomavirus DNA sequences
US5863717A (en) * 1989-11-03 1999-01-26 Abbott Laboratories Use of conserved oligonucleotide primers to amplify human papillomavirus DNA sequences
WO1995004748A1 (en) * 1993-08-09 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating viral processes
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEWIS ET AL., ANTIVIRAL RESEARCH, vol. 34, 1997, pages A72, ABSTRACT NO. 106, XP002949116 *
ROBERTS ET AL., ANTIVIRAL RESEARCH, vol. 34, 1997, pages A71, ABSTRACT NO. 105, XP002949115 *
See also references of EP1315507A4 *

Also Published As

Publication number Publication date
EP1315507A2 (en) 2003-06-04
WO2001077294A2 (en) 2001-10-18
EP1315507A4 (en) 2004-06-16
CA2406485A1 (en) 2001-10-18
JP2004501614A (en) 2004-01-22
AU2001257604A1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
EP1633302A4 (en) MODULATION OF APOLIPOPROTEIN EXPRESSION (A)
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2002036743A3 (en) Antisense modulation of calreticulin expression
EP1417351A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN EXPRESSION (A)
WO2007099432A3 (en) Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2002064766A3 (en) Bax-responsive genes for drug target identification in yeast and fungi
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2004048522A3 (en) Modulation of huntingtin interacting protein 2 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO1996039501A3 (en) Oligonucleotides specific for human papillomavirus
WO2001077294A3 (en) Hpv-specific short-mers
WO2004043394A3 (en) Modulation of huntingtin interacting protein 1 expression
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
EP1248633A4 (en) ANTISENSE MODULATION OF GLYCOGENE SYNTHASE KINASE 3 BETA EXPRESSION
PT1294874E (en) CD154 VARIANTS AND THEIR USES
EP1248635A4 (en) ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 ALPHA EXPRESSION
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2001051489A3 (en) Methods for lowering uric acid levels
WO2004045527A3 (en) Modulation of nima-related kinase 6 expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO1999021005A3 (en) Pharmaceutical grade st. john's wort
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2004048531A3 (en) Modulation of death-associated protein kinase 1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 575148

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2406485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001257604

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001931140

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001931140

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001931140

Country of ref document: EP